An Oncology Technician Specialist Talks Canine Lymphoma | A Vet2Vet Tech Takeover Conversation

Canine lymphoma is one of the most diagnosed cancers in veterinary medicine. The “gold standard” treatment for canine lymphoma remains an alternating drug, chemotherapy protocol, which can be costly or may not be offered in some areas. Often, referral to an oncologist may not be possible and a general practitioner may not be adequately prepared or trained in chemotherapy delivery. Laverdia-CA1 (verdinexor tablets) is an oral treatment for canine lymphoma that is given at home by the pet owner. This new targeted therapy adds another potential option for treating lymphoma in a canine patient and offers pet owners hope when referral to a veterinary oncologist or specialized chemotherapy may not be accessible. Veterinary technicians can play an important role in obtaining diagnostic samples needed for diagnosis or staging tests, but they are also a crucial part of the team when it comes to communicating with pet owners. In this “Vet Tech Takeover” edition of our popular Vet2Vet videos, learn about Laverdia-CA1 and why it’s important to empower veterinary technicians to aid in the diagnosis, treatment and client education of canine lymphoma. Important Safety Information For use in dogs only. Laverdia™-CA1 (verdinexor tablets) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for 3 days following treatment. Laverdia-CA1 can affect male fertility based on animal studies and studies in humans. Wear protective disposable chemotherapy resistant gloves when handling Laverdia-CA1 to avoid direct exposure to moistened, broken or crushed tablets or biological waste from the treated dog (feces, urine, saliva, or vomit). Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia-CA1 is a possible teratogen and can affect female and male fertility. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. The most commonly reported adverse reactions in dogs include anorexia, weight loss, vomiting, diarrhea, lethargy, polyuria, polydipsia, elevated liver enzymes and thrombocytopenia. Please see package insert or visit for full prescribing information.